Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 39 out of 100. Risk factors

Topic: Risk, prevention and care in population studies

Recruitment strategies are tailored in collaboration with community organizations to align with each language group's preferences, including adjusting the blood draw and interview sequence and hosting group blood draws where participants completed the procedure together, fostering a sense of community and reducing anxiety. Engaging in outreach events and providing culturally relevant incentives (i.e. Asian grocery store gift cards) helped foster trust and encourage retention. As of January 23, 2025, 252 participants have enrolled (112 Vietnamese, 56 Korean, 84 Chinese), with 217 completing both blood draw and interview, and the remaining participants awaiting scheduling. The ARISE pilot study demonstrates that collaborations with community partners played an important role in facilitating successful recruitment and study completion, specifically in conducting cognitive assessments and collecting blood samples with older Asian Americans in ADRD research. Future findings will be crucial in guiding future ADRD research in underrepresented populations.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Ching, A., Wong, A., Nam, B., Tzuang, M., Nguyen, L., Yum, S., et al. (2025). Asian Americans & Racism: Individual and Structural Experiences (ARISE) Pilot Study: Cultural and Linguistic Considerations in Studying Chinese, Vietnamese, and Korean American Older Adults. Alzheimer s & Dementia. https://doi.org/10.1002/alz70857_107405

Vancouver

Ching A, Wong A, Nam B, Tzuang M, Nguyen L, Yum S, et al. Asian Americans & Racism: Individual and Structural Experiences (ARISE) Pilot Study: Cultural and Linguistic Considerations in Studying Chinese, Vietnamese, and Korean American Older Adults. Alzheimer s & Dementia. 2025. doi:10.1002/alz70857_107405. PMID: 41452246.

BibTeX

@article{ching2025-41452246,
  author  = {Ching, Annie and Wong, Anson and Nam, Bora and Tzuang, Marian and Nguyen, Linda and Yum, Seoyeon and Deng, Jessie and Huang, Daren and others},
  title   = {{Asian Americans \& Racism: Individual and Structural Experiences (ARISE) Pilot Study: Cultural and Linguistic Considerations in Studying Chinese, Vietnamese, and Korean American Older Adults}},
  journal = {Alzheimer s \& Dementia},
  year    = {2025},
  doi     = {10.1002/alz70857_107405},
  pmid    = {41452246},
  url     = {https://doi.org/10.1002/alz70857_107405}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.

Key findings

Why it matters

This pilot study describes ways to recruit older Chinese, Vietnamese, and Korean Americans into Alzheimer's disease and related dementias research, such as community partnerships and culturally relevant incentives. It reports no treatment, cure, or prevention findings.

Study details

How this study scored 39/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record 2 of 4; Study design 0 of 12; Strength of evidence 1 of 5; Peer-review validation 10 of 10; How recent 4 of 5; Sample size 2 of 4; Effect reported 0 of 3; Studied in people 3 of 3; Randomised / blinded 0 of 2; Times cited 0 of 7; Citations per year 0 of 5; Impact for its field and year 0 of 6; Cited by studies here 0 of 6; Still being cited 0 of 4; Senior author's track record left out, no data; Institution's track record 2 of 3; Multi-centre collaboration 2 of 3; Indexed in PubMed 2 of 2; Free to read 2 of 2. 37 of the 96 points it could be judged on, which is 39 of 100. Total 39 of 100.37 of the 96 points we could judge = 39 of 100

Published in a peer-reviewed journal. Scored zero for study design, effect reported and randomised / blinded because the record does not state it. We have no data on senior author's track record, so that was left out: it earned 37 of the 96 points we could judge it on, which is 39 out of 100.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (Alzheimer s & Dementia)
Journal's citation record 2 / 4 Alzheimer s & Dementia: journal h-index 228 (OpenAlex, 2026-10-29)
Study design 0 / 12 No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence 1 / 5 Rated “low” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 4 / 5 2025 — within 3 year(s) of the newest study here
Sample size 2 / 4 252 participants
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 3 / 3 Studied in people (participant count stated)
Randomised / blinded 0 / 2 No randomisation or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 0 / 7 Cited 0 times (OpenAlex, 2026-10-10)
Citations per year 0 / 5 0.0 citations a year over 3 year(s) since 2025
Impact for its field and year 0 / 6 Cited 0.0× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 0 / 6 No other study in this library cites it
Still being cited 0 / 4 Cited 0 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record — / 4 OpenAlex's profile for last-listed author Van Ta Park holds only 3 work(s), too few to judge a track record — left out of this score
Institution's track record 2 / 3 University of California, San Francisco: institution h-index 1,915 (OpenAlex)
Multi-centre collaboration 2 / 3 OpenAlex lists 5 institution(s) in 1 country
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 41452246)
Free to read 2 / 2 Free to read
Points 37 / 96 Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 37 of the 96 points we could judge it on is 39 out of 100.
Total 39 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Related studies in Risk factors

Also in Risk factors

356 studies in the library are filed under Risk factors with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Risk factors hub.

Similar studies

More on Risk factors

See all studies in Risk factors →